Phase 2 study of biodegradable stents (BD-stent) for refractory benign esophageal strictures after curative treatment of esophageal cancer - Phase 2 study of BD-stent

ational Cancer Center Hospital East0 个研究点目标入组 20 人开始时间: 2012年5月31日最近更新: 2023年10月17日

试验速览

暂无简介。

•1)Delivery system (28F) could not pass the stricture even if any endoscopic dilation was conducted before BD stent insertion. 2)Systemic treatment is indicated for bacterial or fungal infection. 3)Synchronous other cancer except carcinoma in situ, intramucosal carcinoma or watchful waiting prostate cancer. 4)Radiation therapy within 6 months prior to enrollment. 5)Lugol-voiding lesion near the strictures or multiple Lugol-voiding lesion throughout the esophagus. 6)In opioid analgesics therapy. 7)Impossible to discontinue antithrombotic drug. 8)Severe dysphagia. 9)Women during pregnancy or breast-feeding. 10)In chronic treatment with steroids. 11)Patient is judged to be inappropriate for enrollment of the study for any reason by the investigator. 12)Prior treatment using BD stent placement

发起方

ational Cancer Center Hospital East